Diasome
is an Ohio-based biotechnology company that researches and develops transformative cell receptor drugs for the treatment of diabetes... Read moreDiasome
is an Ohio-based biotechnology company that researches and develops transformative cell receptor drugs for the treatment of diabetes... Read more
News
Jun 20, 2025
EIN Presswire
Press Release: Diasome : Diasome Pharmaceuticals Completes Enrollment in Phase 2b OPTI-2 Trial of HDV-Insulin Lispro for Type 1 Diabetes
Aug 15, 2024
SEC
Diasome: Diasome Pharmaceuticals, Inc. has raised $3,090,740 in Funding
Feb 29, 2024
EIN Presswire
Press Release: Diasome : Diasome Pharmaceuticals Launches Groundbreaking OPTI-2 Phase 2b Trial in Type 1 Diabetes
Jan 08, 2024
Crain's Cleveland Business
Diasome: Cleveland-based Diasome Pharmaceuticals announces $9.5 million first close on Series C financing round
Dec 07, 2023
EIN Presswire
Press Release: Diasome : Diasome Pharmaceuticals Announces First Closing of Series C Financing Round
Jun 21, 2023
EIN Presswire
Press Release: Diasome : Diasome's CMO, Dr. Marc Penn, to Unveil Innovative Diabetes Research at ADA Scientific Sessions
Sep 27, 2022
The Business Journals
Diasome: Diasome Pharmaceuticals broke through a challenging funding environment to raise $20M
Sep 22, 2022
The Business Journals
Diasome: Diasome Pharmaceuticals raises at least $20M for diabetes drug trials
Jun 02, 2022
FirstWord Pharma
Diasome: Diasome's HDV-Insulin demonstrates substantial Level 2 hypoglycemia reductions in setting of increased insulin use
Jan 13, 2022
EIN Presswire
Press Release: Diasome : Diasome announces appointment of biopharma thought leader and CEO advisor Peter Tollman, PhD as a new Board Member.
Diasome Competitors
1
2
3
4
5
6
7
8
9
10